Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

39

Revenue 2017

Orencia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Orencia was produced by Bristol-Myers Squibb.

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro Bristol-Myers Squibb’s Orencia (abatacept) was backed as a second-line treatment for moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients (2 years and older), and

Opdivo drives growth at BMS, but US sales slow down

Opdivo drives growth at BMS, but US sales slow down Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia

Opdivo drives gain in BMS sales, but business revamp coming

Opdivo drives gain in BMS sales, but business revamp coming Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.

Shire gives up on Momenta-partnered Humira biosimilar

Shire gives up on Momenta-partnered Humira biosimilar It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
World Heart Day 2020: It's time to make our clinical trials more inclusive
September 29th is World Heart Day, a day dedicated to raising awareness about cardiovascular diseases and how everyone can take steps to prevent them. It’s common knowledge that smoking and...
Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...

Infographics